| Name | Title | Contact Details |
|---|
Fleetworx help the car fleet supply chain work better for everyone. We do this by combining data analytics with technology and expertise. Our specialist services help businesses deliver robust company car fleet management in the UK and across EMEA. We leverage data analytics to dramatically improve decision making and our expertise and practical influence spans the entire fleet supply chain. Our primary objective is to deliver savings, compliance and control and our focused and impartial approach is proven to deliver a significant return on investment. Savings - we provide client-side support in the design and delivery of cost-saving and carbon-saving company car policies. Compliance - we act as an extension of your business. Our robust Management Information System, Fleetworx Centrax, ensure you and your supply chain is fully compliant. Control - we impose tight control on all aspects of your company car fleet, creating a slick, cost-effective and valued reward and retention solution. Our services are particularly valued by fleet generalists in HR/procurement or finance roles who have company car fleet responsibility Contact us at sales@fleetworx.com or visit our website to read our thoughts on the fleet sector and learn more about how we help our clients.
At SIS, were proud to be leaders in collecting, analyzing and distributing the deepest data sets and insights to professional sports teams across MLB, NBA and NFL, while also partnering extensively with the leagues themselves. Our mission is to enrich and optimize the decision-making process for sports teams, sportsbooks, and sports fans. Our vision is to create an unparalleled platform of sporting data and insights through best-in-class technology, products, and partnerships. Our versatility, subject matter expertise, and desire to enhance our partners performance is at the core of what we do. As we enter the next chapter of our trajectory, we are keen to put our data and newfound products to use to improve the sports fan experience, while being a critical part of the supply chain. Our existing database offers unparalleled detail and is updated daily, not just for the 3 professional sports listed, but at the collegiate, international and minor league levels as well. We are also moving further into the real-time data space (for the above noted sports) and into new sports/leagues. A key differentiator for us relative to competition is our flexibility and ability to customize feeds, data points, etc based on specific needs of partners. Company chairman John Dewan founded the company with a group of partners in 2003. John has been a pioneer in sports statistics for more than 40 years and was the founder of STATS Inc. In April of 2021, Audeo Capital announced a significant investment into SIS. Shortly thereafter, a new CEO (Dan Hannigan-Daley) and VP of Product/Engineering (Will Hester) joined the organization following years of success at DraftKings.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
Argo Group is a U.S.-focused underwriter of specialty insurance products in the property and casualty market. We offer a full line of products and services designed to meet the unique coverage and claims-handling needs of businesses. Since 1957, we share a firm commitment to working together with independent agents, wholesale brokers and retail brokerage partners to deliver innovative products for niche markets. Headquartered in New York, were a diverse company with multiple offices in the United States. Our belief that the companys success is linked to our employees drives our commitment to creating an environment and culture of respect where everyone can thrive. We value helping the communities around us, growing alongside our employees through innovation and creating a workplace with work-life balance. Fraud Alert Argo Group is aware of a fraud scam involving false job postings and unsolicited employment offers using our brand. These communications often include hyperlinks and request personal information. If you have any questions about the legitimacy of a job posting, please view all openings here on our website. If you are approached by someone claiming to represent Argo Group, please contact us at either (888) 864-3422 or siuconsults@argogroupus.com.